|
Clinical Studies
Citations 21-30 of 355 total displayed.
|
Past content
(since Nov 2000):
|
- Articles
AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram. Part V: Electrocardiogram Changes Associated With Cardiac Chamber Hypertrophy A Scientific Statement From the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society
- E. William Hancock, Barbara J. Deal, David M. Mirvis, Peter Okin, Paul Kligfield, and Leonard S. Gettes
Circulation published February 19, 2009, doi:10.1161/CIRCULATIONAHA.108.191097
[Abstract]
- Articles
Relations of Matrix Remodeling Biomarkers to Blood Pressure Progression and Incidence of Hypertension in the Community
- Ravi Dhingra, Michael J. Pencina, Peter Schrader, Thomas J. Wang, Daniel Levy, Karol Pencina, Deborah A. Siwik, Wilson S. Colucci, Emelia J. Benjamin, and Ramachandran S. Vasan
Circulation published February 16, 2009, doi:10.1161/CIRCULATIONAHA.108.821769
[Abstract]
- Hypertension
Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy
- Scott D. Solomon, Evan Appelbaum, Warren J. Manning, Anil Verma, Tommy Berglund, Valentina Lukashevich, Cheraz Cherif Papst, Beverly A. Smith, Björn Dahlöf for the Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators
Circulation 2009;119:530-537; published online before print as doi:10.1161/CIRCULATIONAHA.108.826214
[Abstract]
[Full text]
- Statistical Primer for Cardiovascular Research
Optimizing Trial Design: Sequential, Adaptive, and Enrichment Strategies
- Cyrus Mehta, Ping Gao, Deepak L. Bhatt, Robert A. Harrington, Simona Skerjanec, and James H. Ware
Circulation 2009;119:597-605, doi:10.1161/CIRCULATIONAHA.108.809707
[Full text]
- Hypertension
Long-Term Antihypertensive Efficacy and Safety of the Oral Direct Renin Inhibitor Aliskiren: A 12-Month Randomized, Double-Blind Comparator Trial With Hydrochlorothiazide
- Roland E. Schmieder, Thomas Philipp, Javier Guerediaga, Manuel Gorostidi, Beverly Smith, Nicole Weissbach, Mojdeh Maboudian, Jaco Botha, and Hein van Ingen
Circulation 2009;119:417-425; published online before print as doi:10.1161/CIRCULATIONAHA.107.750745
[Abstract]
[Full text]
- Editorials
Assessing Cardiovascular Risk: Should We Discard Diastolic Blood Pressure?
- Giuseppe Schillaci, Matteo Pirro, and Elmo Mannarino
Circulation 2009;119:210-212, doi:10.1161/CIRCULATIONAHA.108.827931
[Full text]
- Epidemiology
Single Versus Combined Blood Pressure Components and Risk for Cardiovascular Disease: The Framingham Heart Study
- Stanley S. Franklin, Victor A. Lopez, Nathan D. Wong, Gary F. Mitchell, Martin G. Larson, Ramachandran S. Vasan, and Daniel Levy
Circulation 2009;119:243-250; published online before print as doi:10.1161/CIRCULATIONAHA.108.797936
[Abstract]
[Full text]
- Articles
Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy
- Scott D. Solomon, Evan Appelbaum, Warren J. Manning, Anil Verma, Tommy Berglund, Valentina Lukashevich, Cheraz Cherif Papst, Beverly A. Smith, Björn Dahlöf for the Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators
Circulation published January 19, 2009, doi:10.1161/CIRCULATIONAHA.108.826214
[Abstract]
- Articles
Long-Term Antihypertensive Efficacy and Safety of the Oral Direct Renin Inhibitor Aliskiren. A 12-Month Randomized, Double-Blind Comparator Trial With Hydrochlorothiazide
- Roland E. Schmieder, Thomas Philipp, Javier Guerediaga, Manuel Gorostidi, Beverly Smith, Nicole Weissbach, Mojdeh Maboudian, Jaco Botha, and Hein van Ingen
Circulation published January 12, 2009, doi:10.1161/CIRCULATIONAHA.107.750745
[Abstract]
- Correspondence
Letter by Kass Regarding Article, "Role of Left Ventricular Stiffness in Heart Failure With Normal Ejection Fraction"
- David A. Kass
Circulation 2009;119:e4, doi:10.1161/CIRCULATIONAHA.108.788729
[Full text]
|
|
